Abstract
Fibromyalgia (FM) is continuing to be a challenging and confusing disorder for researchers and clinicians with its diverse symptoms, poorly understood etiology and pathophysiology. The use of multiple outcome variables reflecting the complexity of FM and co-morbid syndromes, makes it difficult to evaluate the efficacy or effectiveness of the treatment in clinical trials. Additionally researchers inevitably rely on patients self reported outcome data, which is prone to error and bias. In this paper, new researches in the field of FM and practical issues on methodology of pain assessment (visual analogueue scales, paper or electronic diaries and compliance), core outcome domains in chronic pain assessment (IMMPACT recommendations), and advances in neuroimaging techniques like functional magnetic resonance imaging have been reviewed. Consequently, clinicians and researchers have various highly validated and adequate outcome domains to assess FM symptoms and new researches continue to add new valuable domains. Nevertheless the current problem is to conclude, which treatment works best for whom and which are the outcome domains suitable for FM patients or patients subgroups with different prominent features. Standardised and appropriate core outcome domains for FM clinical trails will encourage more complete investigations, relevant outcome reporting and well-designed multicenter trials.
Keywords: Fibromyalgia, core outcome domain, neuroimaging, diary, bias, pain
Current Pharmaceutical Design
Title: New Strategies in Evaluation of Therapeutic Efficacy in Fibromyalgia Syndrome
Volume: 12 Issue: 1
Author(s): Salih Ozgocmen
Affiliation:
Keywords: Fibromyalgia, core outcome domain, neuroimaging, diary, bias, pain
Abstract: Fibromyalgia (FM) is continuing to be a challenging and confusing disorder for researchers and clinicians with its diverse symptoms, poorly understood etiology and pathophysiology. The use of multiple outcome variables reflecting the complexity of FM and co-morbid syndromes, makes it difficult to evaluate the efficacy or effectiveness of the treatment in clinical trials. Additionally researchers inevitably rely on patients self reported outcome data, which is prone to error and bias. In this paper, new researches in the field of FM and practical issues on methodology of pain assessment (visual analogueue scales, paper or electronic diaries and compliance), core outcome domains in chronic pain assessment (IMMPACT recommendations), and advances in neuroimaging techniques like functional magnetic resonance imaging have been reviewed. Consequently, clinicians and researchers have various highly validated and adequate outcome domains to assess FM symptoms and new researches continue to add new valuable domains. Nevertheless the current problem is to conclude, which treatment works best for whom and which are the outcome domains suitable for FM patients or patients subgroups with different prominent features. Standardised and appropriate core outcome domains for FM clinical trails will encourage more complete investigations, relevant outcome reporting and well-designed multicenter trials.
Export Options
About this article
Cite this article as:
Ozgocmen Salih, New Strategies in Evaluation of Therapeutic Efficacy in Fibromyalgia Syndrome, Current Pharmaceutical Design 2006; 12 (1) . https://dx.doi.org/10.2174/138161206775193271
DOI https://dx.doi.org/10.2174/138161206775193271 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD)
Current Medicinal Chemistry Induction of RhoGAP and Pathological Changes Characteristic of Alzheimers Disease by UAHFEMF Discharge in Rat Brain
Current Alzheimer Research Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry Physical Activity Level and Motor Aptitude: Motor Domains and Identification Capacity of Brazilian Insufficiently Active Older Adults
Current Aging Science Human Cognition Assessment in Drug Research
Current Pharmaceutical Design Synthetic Cathinones: A New Public Health Problem
Current Neuropharmacology Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction
Current Neuropharmacology Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy Phasic Dopamine Release in Appetitive Behaviors and Drug Addiction
Current Drug Abuse Reviews Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Modulation of the Intrinsic Properties of Motoneurons by Serotonin
Current Pharmaceutical Design